Akorn-Strides, LLC (AKRX) Announces FDA Approvals for Famotidine Injection USP
More News related to AKRX
- Beacon Equity Issues Technical Trade Alerts on Market Movers: ELRA, VLNC, DLIA, AKRX, ABX, GLD
- Akorn (AKRX) Enters 10-Year Mfg. Supply Agreement with Undisclosed Ophthalmic Company
- Akorn Enters into an Exclusive Contract Manufacturing Supply Agreement
- Akorn (AKRX) Announces FDA NDA Approval for IC-Green(TM) for Injection, USP
- Akorn, Inc. Announces First Lyophilized Product Approval For Decatur, IL: IC-Green(TM) for Injection, USP
More News related to FDA
- Advanced Medical Optics (EYE) Granted FDA Premarket Approval of Healon D(R) Viscoelastic
- GTC Biotherapeutics (GTCB) Announces FDA Accepts ATryn(R) BLA Filing
- Genentech and OSI Phama Said Avastin/Tarceva Combo Fails As Second-Line Treatment For Lung Cancer
Akorn-Strides, LLC announced the approvals of two ANDAs for Famotidine Injection USP, 20 mg/2mL Single-Dose Vials and 40 mg/4mL & 200 mg/20mL Multiple-Dose Vials. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab Limited (NSE: STAR)(BSE: 532531). The primary mission for the Joint Venture is to develop liquid, lyophilized and dry powder formulations of generic injectable products targeting several therapeutic markets with a major focus on anti-infectives, analgesics and CNS medicines.
Related Categories
Corporate NewsFDA
Stocks Mentioned
-0.41Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
